Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-defined patient populations and the FDA’s approval of several targeted therapies in 2015 have positioned NSCLC at the forefront of personalized medicine in oncology and resulted in an evolving treatment landscape for the disease. This analysis provides insight on current use of approved therapies for NSCLC in the United States and on oncologists’ perception of these therapies.
Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.
Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...
Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...